Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
164.36
-1.43 (-0.86%)
Streaming Delayed Price
Updated: 10:05 AM EST, Nov 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Why Biogen Stock Leaped Nearly 5% Higher Today
April 24, 2024
The company came out swinging with its first set of quarterly earnings for this year.
Via
The Motley Fool
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
April 24, 2024
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA...
Via
Benzinga
Exposures
Product Safety
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
April 24, 2024
Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the...
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
Where Biogen Stands With Analysts
April 11, 2024
Via
Benzinga
Looking Into Biogen's Recent Short Interest
April 03, 2024
Via
Benzinga
Forecasting The Future: 18 Analyst Projections For Biogen
March 25, 2024
Via
Benzinga
Biogen (BIIB) Q1 2024 Earnings Call Transcript
April 24, 2024
BIIB earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
April 24, 2024
Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.
Via
Benzinga
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
April 24, 2024
BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
April 24, 2024
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares?
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
April 24, 2024
Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m
Via
Benzinga
A Closer Look at 21 Analyst Recommendations For Biogen
March 05, 2024
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
March 29, 2024
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...
Via
Talk Markets
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Tuesday Talk: Big-Tech Under Attack
March 26, 2024
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.
Via
Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
March 25, 2024
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Via
InvestorPlace
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.
Via
Benzinga
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
March 20, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
March 16, 2024
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...
Via
Talk Markets
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers
March 08, 2024
February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Via
MarketBeat
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
March 08, 2024
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA...
Via
Benzinga
Exposures
Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
March 08, 2024
The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab.
Via
Investor's Business Daily
Exposures
Product Safety
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.